Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Jan 14, 2022 7:43pm
190 Views
Post# 34319397

RE:4 pm PR

RE:4 pm PRYou can all chill out and enjoy your weekend. Chances are pretty high they will not proceed in NASH without a partner. If so, there is no reason to raise money since if they have a partner they will provide the funding and if they do not, they likely will not move forward. Maybe if cancer turns out promising and the stock price jumps, they do an offering to fund NASH, but if they enjoy their jobs, they probably don't do another ONO. Another reason for an offering would be be an acquisition, but that seems like a long shot. We would be better off focusing on the phase 1a trial rather than being concerned about an unlikely offering, at least anytime soon.
palinc2000 wrote: It almost feels that way.....I hope I am wrong but the trading feels that way

Seeme like the re is a target closing price 
Friday afternoon jitters!!!


<< Previous
Bullboard Posts
Next >>